Yokogawa Selected as MAC for Construction of Europe’s Largest Renewable Hydrogen Plant

Yokogawa Electric Corporation announced today that it has been selected by Shell Plc to be the main automation contractor (MAC) for the construction of its Holland Hydrogen I plant in the Dutch port of Rotterdam.

Illustration of the proposed Holland Hydrogen I site. Image Credit: Shell

The Holland Hydrogen I plant will produce renewable hydrogen by using electricity from an offshore wind farm and will be Europe’s largest renewable hydrogen plant once operational in 2025. In its role as MAC, Yokogawa will optimize operations at the plant by closely integrating its systems and equipment.

The Holland Hydrogen I plant will have a 200 megawatts (MW) electrolyser that will produce up to 60,000 kilograms of green hydrogen per day. The green hydrogen produced at this plant will be transported via a pipeline to the Shell Energy and Chemicals Park Rotterdam, where it will replace some of the grey hydrogen used in the refinery, partially decarbonizing the facility’s production of energy products like gasoline, diesel and jet fuel.

Koji Nakaoka, Yokogawa vice president and head of the company’s Energy & Sustainability Business Headquarters and Global Sales Headquarters, said, “Our company aims to play a leading role in achieving a world in which systems are closely integrated, based on the system of systems (SoS) concept. In the hydrogen supply chain, there are individual systems for functions such as production, pipeline transport, storage, and supply, each of which is owned by a different entity. Through participation in projects that help our customers achieve progress in their decarbonization strategies and add value to their enterprises, Yokogawa will continue working to realize a sustainable society.”

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.